JP2012503986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012503986A5 JP2012503986A5 JP2011529291A JP2011529291A JP2012503986A5 JP 2012503986 A5 JP2012503986 A5 JP 2012503986A5 JP 2011529291 A JP2011529291 A JP 2011529291A JP 2011529291 A JP2011529291 A JP 2011529291A JP 2012503986 A5 JP2012503986 A5 JP 2012503986A5
- Authority
- JP
- Japan
- Prior art keywords
- retrovirus
- polynucleotide
- sequence
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001430294 unidentified retrovirus Species 0.000 claims 31
- 108091033319 polynucleotide Proteins 0.000 claims 27
- 102000040430 polynucleotide Human genes 0.000 claims 27
- 239000002157 polynucleotide Substances 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 17
- 230000001177 retroviral effect Effects 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 13
- 125000003729 nucleotide group Chemical group 0.000 claims 13
- 241000714177 Murine leukemia virus Species 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 6
- 241000713869 Moloney murine leukemia virus Species 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 230000002062 proliferating effect Effects 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 108091026890 Coding region Proteins 0.000 claims 4
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 4
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 4
- 241001663880 Gammaretrovirus Species 0.000 claims 4
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 241000710188 Encephalomyocarditis virus Species 0.000 claims 2
- 241000714165 Feline leukemia virus Species 0.000 claims 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 102100034349 Integrase Human genes 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 108020005067 RNA Splice Sites Proteins 0.000 claims 2
- 108091027981 Response element Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 108010042121 probasin Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 101710091045 Envelope protein Proteins 0.000 claims 1
- 101710177291 Gag polyprotein Proteins 0.000 claims 1
- 101000807008 Homo sapiens Uracil phosphoribosyltransferase homolog Proteins 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 claims 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 claims 1
- 108010076039 Polyproteins Proteins 0.000 claims 1
- 101710188315 Protein X Proteins 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 108700005075 Regulator Genes Proteins 0.000 claims 1
- 101000938863 Toxoplasma gondii Uracil phosphoribosyltransferase Proteins 0.000 claims 1
- 102100037717 Uracil phosphoribosyltransferase homolog Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 1
- 229960004413 flucytosine Drugs 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108010089520 pol Gene Products Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 238000010839 reverse transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10066608P | 2008-09-26 | 2008-09-26 | |
| US61/100,666 | 2008-09-26 | ||
| US12061808P | 2008-12-08 | 2008-12-08 | |
| US61/120,618 | 2008-12-08 | ||
| US18682309P | 2009-06-13 | 2009-06-13 | |
| US61/186,823 | 2009-06-13 | ||
| PCT/US2009/058510 WO2010045002A2 (en) | 2008-09-26 | 2009-09-26 | Gene therapy vectors and cytosine deaminases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015097980A Division JP6062485B2 (ja) | 2008-09-26 | 2015-05-13 | 遺伝子治療ベクターおよびシトシンデアミナーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012503986A JP2012503986A (ja) | 2012-02-16 |
| JP2012503986A5 true JP2012503986A5 (enExample) | 2012-11-15 |
| JP5771147B2 JP5771147B2 (ja) | 2015-08-26 |
Family
ID=42060421
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529291A Expired - Fee Related JP5771147B2 (ja) | 2008-09-26 | 2009-09-26 | 遺伝子治療ベクターおよびシトシンデアミナーゼ |
| JP2011529292A Expired - Fee Related JP5684130B2 (ja) | 2008-09-26 | 2009-09-26 | 組換えベクター |
| JP2015004923A Expired - Fee Related JP5992548B2 (ja) | 2008-09-26 | 2015-01-14 | 組換えベクター |
| JP2015097980A Expired - Fee Related JP6062485B2 (ja) | 2008-09-26 | 2015-05-13 | 遺伝子治療ベクターおよびシトシンデアミナーゼ |
| JP2016159893A Expired - Fee Related JP6523224B2 (ja) | 2008-09-26 | 2016-08-17 | 組換えベクター |
| JP2019086133A Pending JP2019141088A (ja) | 2008-09-26 | 2019-04-26 | 組換えベクター |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529292A Expired - Fee Related JP5684130B2 (ja) | 2008-09-26 | 2009-09-26 | 組換えベクター |
| JP2015004923A Expired - Fee Related JP5992548B2 (ja) | 2008-09-26 | 2015-01-14 | 組換えベクター |
| JP2015097980A Expired - Fee Related JP6062485B2 (ja) | 2008-09-26 | 2015-05-13 | 遺伝子治療ベクターおよびシトシンデアミナーゼ |
| JP2016159893A Expired - Fee Related JP6523224B2 (ja) | 2008-09-26 | 2016-08-17 | 組換えベクター |
| JP2019086133A Pending JP2019141088A (ja) | 2008-09-26 | 2019-04-26 | 組換えベクター |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8722867B2 (enExample) |
| EP (4) | EP3460061A1 (enExample) |
| JP (6) | JP5771147B2 (enExample) |
| KR (3) | KR102025502B1 (enExample) |
| CN (4) | CN102227501B (enExample) |
| AU (1) | AU2009303690B2 (enExample) |
| BR (1) | BRPI0919113A2 (enExample) |
| CA (1) | CA2738472A1 (enExample) |
| CO (1) | CO6362050A2 (enExample) |
| DK (1) | DK2346995T3 (enExample) |
| EA (2) | EA201790824A3 (enExample) |
| ES (2) | ES2709481T3 (enExample) |
| IL (3) | IL211847A (enExample) |
| MX (3) | MX2011003039A (enExample) |
| MY (1) | MY156333A (enExample) |
| NZ (1) | NZ592070A (enExample) |
| WO (2) | WO2010036986A2 (enExample) |
| ZA (1) | ZA201102115B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69940521D1 (de) | 1998-10-01 | 2009-04-16 | Univ Southern California | Retrovirales genübertragungssystem und entsprechendes verwendungverfahren |
| CN102076215A (zh) | 2008-06-30 | 2011-05-25 | 托卡根公司 | 5-氟胞嘧啶制剂及其用途 |
| WO2010036986A2 (en) * | 2008-09-26 | 2010-04-01 | Tocagen Inc. | Recombinant vectors |
| US8829173B2 (en) * | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| SG176890A1 (en) * | 2009-06-17 | 2012-01-30 | Tocagen Inc | Producer cells for replication competent retroviral vectors |
| CA2836977A1 (en) * | 2010-06-06 | 2011-12-15 | Benjamin R. Tenoever | Recombinant rna viruses and uses thereof |
| WO2012009711A2 (en) | 2010-07-16 | 2012-01-19 | Tocagen Inc. | Retrovirus detection |
| EP2633321B1 (en) | 2010-10-31 | 2017-12-06 | Tocagen Inc. | Antisera assays for mlv related viruses in humans and other mammals |
| WO2012058673A2 (en) * | 2010-10-31 | 2012-05-03 | Tocagen Inc. | Enhanced cancer treatment and monitoring using recombinant vectors |
| TWI486446B (zh) * | 2011-06-02 | 2015-06-01 | Taipei Veterans General Hospital | 治療感染性與惡性疾病的標靶化學治療藥物的形成方法 |
| KR101554678B1 (ko) * | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
| EP2909324B1 (en) | 2012-10-25 | 2020-02-26 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
| CN105073779A (zh) * | 2012-11-15 | 2015-11-18 | 埃斯佩兰斯医药公司 | 促卵泡激素(fsh)/裂解结构域融合构建体与其制备和使用的方法 |
| US9642921B2 (en) | 2012-12-20 | 2017-05-09 | Tocagen Inc. | Cancer combination therapy and recombinant vectors |
| US20160175388A1 (en) | 2013-06-15 | 2016-06-23 | Tocagen Inc. | Immunosuppressive components associated with retroviral replicating vectors |
| EP3030659A4 (en) * | 2013-08-05 | 2017-01-11 | Tocagen Inc. | Recombinant vector with optimized a-bulge |
| CN103966260A (zh) * | 2014-03-07 | 2014-08-06 | 山东农业大学 | 一种基于J亚群禽白血病病毒pol基因保守序列的siRNA重组干扰载体及其制备方法和应用 |
| US11230719B2 (en) | 2014-03-26 | 2022-01-25 | Denovo Biopharma Llc | Retroviral vector having immune-stimulating activity |
| SG11201608393TA (en) | 2014-04-10 | 2016-11-29 | Seattle Children S Hospital Dba Seattle Children S Res Inst | Transgene genetic tags and methods of use |
| WO2015168102A2 (en) * | 2014-04-28 | 2015-11-05 | Board Of Regents, The University Of Texas System | Prolonged protein stabilization by resveratrol |
| CN104557602B (zh) * | 2015-01-07 | 2016-08-17 | 华东师范大学 | 三环二萜衍生物及其制备方法、及其在制备抗肿瘤药物中的应用 |
| US11458167B2 (en) | 2015-08-07 | 2022-10-04 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
| EA201890640A1 (ru) * | 2015-09-04 | 2018-09-28 | Токаджен Инк. | Рекомбинантные векторы, содержащие пептид 2а |
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| CN110225977B (zh) | 2016-11-29 | 2023-05-05 | 阿迪雷尔有限公司 | 基因治疗载体系统和药物前体基因 |
| CN107058314B (zh) * | 2016-11-30 | 2020-09-04 | 暨南大学 | 一种启动子及其应用 |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| KR102424850B1 (ko) | 2017-06-30 | 2022-07-22 | 인스크립타 인코포레이티드 | 자동 세포 처리 방법, 모듈, 기기 및 시스템 |
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| MX2020000495A (es) * | 2017-07-14 | 2020-08-20 | Oncorus Inc | Polinucleotidos encapsulados y metodos de uso. |
| US20190191975A1 (en) * | 2017-12-27 | 2019-06-27 | Ethicon Llc | Fluorescence imaging in a light deficient environment |
| AR114269A1 (es) * | 2018-02-26 | 2020-08-12 | Ablynx Nv | Secuencias nucleotídicas mejoradas que codifican para péptidos de unión |
| US10526598B2 (en) | 2018-04-24 | 2020-01-07 | Inscripta, Inc. | Methods for identifying T-cell receptor antigens |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| CN110396504A (zh) * | 2018-04-25 | 2019-11-01 | 江苏省原子医学研究所 | 一种具有肿瘤靶向性的重组痘苗病毒及其制备方法、用途 |
| AU2019292919A1 (en) | 2018-06-30 | 2021-03-11 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| EP3653716A1 (en) * | 2018-11-19 | 2020-05-20 | HSF Pharmaceuticals | Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore |
| EP3947691A4 (en) | 2019-03-25 | 2022-12-14 | Inscripta, Inc. | SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| CN113939593A (zh) | 2019-06-06 | 2022-01-14 | 因思科瑞普特公司 | 用于递归的核酸指导的细胞编辑的处治 |
| US11531112B2 (en) | 2019-06-20 | 2022-12-20 | Cilag Gmbh International | Offset illumination of a scene using multiple emitters in a hyperspectral, fluorescence, and laser mapping imaging system |
| US11012599B2 (en) | 2019-06-20 | 2021-05-18 | Ethicon Llc | Hyperspectral imaging in a light deficient environment |
| US11389066B2 (en) | 2019-06-20 | 2022-07-19 | Cilag Gmbh International | Noise aware edge enhancement in a pulsed hyperspectral, fluorescence, and laser mapping imaging system |
| US11516387B2 (en) | 2019-06-20 | 2022-11-29 | Cilag Gmbh International | Image synchronization without input clock and data transmission clock in a pulsed hyperspectral, fluorescence, and laser mapping imaging system |
| US10952619B2 (en) | 2019-06-20 | 2021-03-23 | Ethicon Llc | Hyperspectral and fluorescence imaging and topology laser mapping with minimal area monolithic image sensor |
| US12440085B2 (en) | 2019-06-20 | 2025-10-14 | Cilag Gmbh International | Image synchronization without input clock and data transmission clock in a pulsed laser mapping imaging system |
| US11311183B2 (en) | 2019-06-20 | 2022-04-26 | Cilag Gmbh International | Controlling integral energy of a laser pulse in a fluorescence imaging system |
| US11122967B2 (en) | 2019-06-20 | 2021-09-21 | Cilag Gmbh International | Driving light emissions according to a jitter specification in a fluorescence imaging system |
| US11237270B2 (en) | 2019-06-20 | 2022-02-01 | Cilag Gmbh International | Hyperspectral, fluorescence, and laser mapping imaging with fixed pattern noise cancellation |
| US11360028B2 (en) | 2019-06-20 | 2022-06-14 | Cilag Gmbh International | Super resolution and color motion artifact correction in a pulsed hyperspectral, fluorescence, and laser mapping imaging system |
| US11788963B2 (en) | 2019-06-20 | 2023-10-17 | Cilag Gmbh International | Minimizing image sensor input/output in a pulsed fluorescence imaging system |
| US11712155B2 (en) | 2019-06-20 | 2023-08-01 | Cilag GmbH Intenational | Fluorescence videostroboscopy of vocal cords |
| US12126887B2 (en) | 2019-06-20 | 2024-10-22 | Cilag Gmbh International | Hyperspectral and fluorescence imaging with topology laser scanning in a light deficient environment |
| US12013496B2 (en) | 2019-06-20 | 2024-06-18 | Cilag Gmbh International | Noise aware edge enhancement in a pulsed laser mapping imaging system |
| CN114127121B (zh) | 2019-08-12 | 2025-04-11 | 北京恩瑞尼生物科技股份有限公司 | 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物 |
| KR102281858B1 (ko) | 2019-09-11 | 2021-07-26 | 주식회사 쎌바이오텍 | 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물 |
| TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
| WO2021102059A1 (en) | 2019-11-19 | 2021-05-27 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| CN114829607A (zh) | 2019-12-18 | 2022-07-29 | 因思科瑞普特公司 | 用于体内检测核酸引导的核酸酶编辑的细胞的Cascade/dCas3互补测定 |
| WO2021154706A1 (en) | 2020-01-27 | 2021-08-05 | Inscripta, Inc. | Electroporation modules and instrumentation |
| US20210332388A1 (en) * | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| CN111944810B (zh) * | 2020-07-29 | 2022-05-27 | 中国农业大学 | 靶向敲除TNFα基因的sgRNA和敲除TNFα基因的猪胚胎成纤维细胞系及其应用 |
| EP4214314A4 (en) | 2020-09-15 | 2024-10-16 | Inscripta, Inc. | Crispr editing to embed nucleic acid landing pads into genomes of live cells |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| US11306298B1 (en) | 2021-01-04 | 2022-04-19 | Inscripta, Inc. | Mad nucleases |
| US11332742B1 (en) | 2021-01-07 | 2022-05-17 | Inscripta, Inc. | Mad nucleases |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| TW202332694A (zh) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | 血清半衰期延長之ｐｄ－ｌ１結合多肽 |
| EP4413038A1 (en) | 2021-10-07 | 2024-08-14 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
| LT7046B (lt) | 2022-04-15 | 2024-02-12 | Vilniaus Universitetas | Hidrolazės ir jų panaudojimas |
| KR20250006965A (ko) | 2022-04-29 | 2025-01-13 | 퓨리노미아 바이오테크, 아이엔씨. | 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물 |
| CN118697758B (zh) * | 2024-05-31 | 2025-10-21 | 河北大学 | miR-128-1-5p的应用 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| CA2018273C (en) | 1989-06-09 | 1999-04-06 | Peter D. Senter | Thermally stable cytosine deaminase |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5770428A (en) * | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
| JPH08511156A (ja) | 1993-04-06 | 1996-11-26 | アメリカ合衆国 | テナガザル白血球ウイルスベースのレトロウイルスベクター |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| JPH09504429A (ja) | 1993-10-12 | 1997-05-06 | チロン ビアジーン，インコーポレイティド | 組換えウイルスの保存方法 |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| AU708972B2 (en) | 1994-11-07 | 1999-08-19 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US20030157070A1 (en) | 1994-12-30 | 2003-08-21 | Jolly Douglas J. | High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations |
| US6117681A (en) | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
| JPH11507205A (ja) | 1995-04-27 | 1999-06-29 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子受容体 |
| US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| WO1998006842A1 (en) | 1996-08-16 | 1998-02-19 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| ES2316153T3 (es) | 1996-08-16 | 2009-04-01 | Human Genome Sciences, Inc. | Endoquina alfa humana. |
| JP2001504325A (ja) | 1996-09-27 | 2001-04-03 | マキシジェン，インコーポレイテッド | 回帰的配列シャフリングおよび選択による遺伝子治療の最適化のための方法 |
| BR9612752A (pt) | 1996-10-25 | 2000-01-18 | Human Genome Sciences Inc | Neutrocina |
| ATE321855T1 (de) | 1997-01-14 | 2006-04-15 | Human Genome Sciences Inc | Tumor-nekrose-faktor rezeptor 5 |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| DE69835360T2 (de) | 1997-01-17 | 2007-08-16 | Maxygen, Inc., Redwood City | EVOLUTION Prokaryotischer GANZER ZELLEN DURCH REKURSIVE SEQUENZREKOMBINATION |
| ATE362982T1 (de) | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
| ATE418608T1 (de) | 1997-03-18 | 2009-01-15 | Novozymes As | Methode zur herstellung einer bibliothek mittels dna-shuffling |
| CN1249784A (zh) | 1997-03-18 | 2000-04-05 | 诺沃挪第克公司 | 一种体外构建dna文库的方法 |
| US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
| US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| WO1998054202A1 (en) | 1997-05-30 | 1998-12-03 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr10 |
| WO1998056892A1 (en) | 1997-06-11 | 1998-12-17 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr9 |
| WO1999020742A2 (en) | 1997-10-20 | 1999-04-29 | Universita' Degli Studi Di Padova | A packaging cell line producing siv-pseudotyped mlv |
| AU1124499A (en) | 1997-10-28 | 1999-05-17 | Maxygen, Inc. | Human papillomavirus vectors |
| AU1449499A (en) | 1997-10-31 | 1999-05-24 | Maxygen, Incorporated | Modification of virus tropism and host range by viral genome shuffling |
| JP3712255B2 (ja) | 1997-12-08 | 2005-11-02 | カリフォルニア・インスティチュート・オブ・テクノロジー | ポリヌクレオチドおよびポリペプチド配列を生成するための方法 |
| FR2773561A1 (fr) | 1998-01-15 | 1999-07-16 | Centre Nat Rech Scient | Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus |
| CA2320431A1 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Targeting of genetic vaccine vectors |
| JP2002507393A (ja) | 1998-02-11 | 2002-03-12 | マキシジェン， インコーポレイテッド | 抗原ライブラリー免疫 |
| US6451304B1 (en) | 1998-03-09 | 2002-09-17 | The Regents Of The University Of California | Method for retrovirus vector production by separated gag and pol expression |
| AU758155B2 (en) | 1998-04-29 | 2003-03-13 | Oklahoma Medical Research Foundation | Construction of retroviral producer cells from adenoviral and retroviral vectors |
| US7001733B1 (en) | 1998-05-12 | 2006-02-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement |
| GB9810752D0 (en) | 1998-05-19 | 1998-07-15 | Glaxo Group Ltd | Cystosine deaminase gene |
| US6448390B1 (en) | 1998-05-20 | 2002-09-10 | The University Of Tennessee Research Corporation | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy |
| AU761570B2 (en) | 1998-06-29 | 2003-06-05 | Bristol-Myers Squibb Company | Methods for generating highly diverse libraries |
| US6264940B1 (en) | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
| FR2782323B1 (fr) | 1998-08-12 | 2002-01-11 | Proteus | Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues |
| IL140441A0 (en) | 1998-09-29 | 2002-02-10 | Maxygen Inc | Shuffling of codon altered genes |
| DE69940521D1 (de) | 1998-10-01 | 2009-04-16 | Univ Southern California | Retrovirales genübertragungssystem und entsprechendes verwendungverfahren |
| US6899871B2 (en) | 1998-10-01 | 2005-05-31 | University Of Southern California | Gene delivery system and methods of use |
| US6576463B1 (en) | 1999-01-15 | 2003-06-10 | The Regents Of The University Of California | Hybrid vectors for gene therapy |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| AU2415200A (en) | 1999-01-18 | 2000-08-01 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| JP2002534966A (ja) | 1999-01-19 | 2002-10-22 | マキシジェン， インコーポレイテッド | オリゴヌクレオチド媒介核酸組換え |
| CA2371946A1 (en) | 1999-04-29 | 2000-11-09 | Aarhus University | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
| GB2368846B (en) | 1999-07-08 | 2004-08-25 | Univ California | Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use |
| WO2001040488A1 (en) | 1999-11-30 | 2001-06-07 | Novartis Ag | Increased transgene expression in retroviral vectors having scaffold attachment region |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| WO2001064864A2 (en) | 2000-02-28 | 2001-09-07 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| AU2001292711A1 (en) | 2000-09-18 | 2002-03-26 | Genetic Therapy, Inc. | Stress resistant retroviruses |
| US20030003565A1 (en) * | 2000-11-27 | 2003-01-02 | Dubensky Thomas W. | Functional lentiviral vector from an MLV-based backbone |
| US7226779B2 (en) | 2001-01-30 | 2007-06-05 | The United States Of America As Represented By The Department Of Health And Human Services | Hybrid adenoviral vector |
| DE10111433A1 (de) | 2001-03-09 | 2002-09-19 | Bundesrepublik Deutschland Let | Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen |
| JP2002335965A (ja) | 2001-05-14 | 2002-11-26 | Japan Science & Technology Corp | 細胞特異的発現複製ベクター |
| DE10143237A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente) |
| AU2002326906C1 (en) * | 2001-09-13 | 2009-01-29 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| FR2832424B1 (fr) | 2001-11-20 | 2004-09-24 | Genethon Iii | Plasmide chimere comprenant un genome retroviral replicatif et utilisations |
| US20030121068A1 (en) * | 2001-11-30 | 2003-06-26 | Paul Orchard | Vector encoding suicide and marker constructs |
| AU2003206815A2 (en) | 2002-02-01 | 2003-09-02 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with PODs |
| MXPA05000647A (es) | 2002-07-17 | 2005-03-31 | Squibb Bristol Myers Co | Mamiferos no humanos transgenicos que expresan un acido nucleico reportero bajo regulacion de los elementos de respuesta de androgenos. |
| EP1534847B1 (en) * | 2002-09-03 | 2015-10-28 | Oxford Biomedica (UK) Limited | Retroviral vector and stable packaging cell lines |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| KR101062140B1 (ko) | 2003-07-21 | 2011-09-05 | 트랜스진 에스.에이. | 향상된 시토신 디아미네이즈 활성을 갖는 폴리펩티드 |
| WO2005086922A2 (en) * | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| WO2005118802A2 (en) | 2004-06-03 | 2005-12-15 | The Regents Of The University Of California | Targeting pseudotyped retroviral vectors |
| US20070003522A1 (en) | 2004-07-08 | 2007-01-04 | Albritton Lorraine M | Methods and compositions for improved retroviral gene and drug delivery |
| BRPI0515735A2 (pt) | 2004-11-04 | 2011-10-11 | Pfizer Prod Inc | tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos |
| AU2005309485A1 (en) * | 2004-11-24 | 2006-06-01 | Nanovector Limited | Viral vectors |
| US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
| WO2006127980A2 (en) | 2005-05-25 | 2006-11-30 | The Regents Of The University Of California | Optimized core promoters and uses therefor |
| US20070048285A1 (en) * | 2005-08-24 | 2007-03-01 | Christopher Baum | Self-inactivating retroviral vector |
| WO2007036233A2 (en) * | 2005-09-30 | 2007-04-05 | Zgene A/S | Dekkera/brettanomyces cytosine deaminases and their use |
| EP2386564B1 (en) * | 2005-10-01 | 2014-07-16 | Charles Stout | Regulatable fusion promoters |
| WO2007044483A2 (en) | 2005-10-07 | 2007-04-19 | President And Fellows Of Harvard College | Attenuated vaccines for non-segmented negative sense rna viruses |
| EP1795596A1 (en) * | 2005-12-08 | 2007-06-13 | Ganymed Pharmaceuticals AG | Composition and methods for therapy and diagnosis of cancer |
| EP2487260B1 (en) * | 2006-01-05 | 2015-07-08 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
| WO2007095201A2 (en) | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | Pseudotyped retroviral vectors and methods of use thereof |
| WO2007107156A2 (en) | 2006-03-17 | 2007-09-27 | Aarhus Universitet | Chimeric viral envelopes |
| JP6092497B2 (ja) * | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| SG173337A1 (en) * | 2006-07-21 | 2011-08-29 | California Inst Of Techn | Targeted gene delivery for dendritic cell vaccination |
| WO2008151633A2 (en) | 2007-06-15 | 2008-12-18 | Skau Aps | Vectors for vaccines against lentivirus infections |
| CN102076215A (zh) | 2008-06-30 | 2011-05-25 | 托卡根公司 | 5-氟胞嘧啶制剂及其用途 |
| WO2010036986A2 (en) * | 2008-09-26 | 2010-04-01 | Tocagen Inc. | Recombinant vectors |
| US8829173B2 (en) * | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| SG176890A1 (en) * | 2009-06-17 | 2012-01-30 | Tocagen Inc | Producer cells for replication competent retroviral vectors |
| AU2011289283B2 (en) | 2010-08-13 | 2015-04-30 | Pioneer Hi-Bred International, Inc. | Chimeric promoters and methods of use |
-
2009
- 2009-09-26 WO PCT/US2009/058512 patent/WO2010036986A2/en not_active Ceased
- 2009-09-26 EP EP18188075.8A patent/EP3460061A1/en not_active Withdrawn
- 2009-09-26 KR KR1020187016894A patent/KR102025502B1/ko not_active Expired - Fee Related
- 2009-09-26 CN CN200980147509.6A patent/CN102227501B/zh not_active Expired - Fee Related
- 2009-09-26 CN CN201510505943.4A patent/CN105274125A/zh active Pending
- 2009-09-26 ES ES09816967T patent/ES2709481T3/es active Active
- 2009-09-26 NZ NZ592070A patent/NZ592070A/en not_active IP Right Cessation
- 2009-09-26 KR KR1020167016947A patent/KR101870056B1/ko not_active Expired - Fee Related
- 2009-09-26 EP EP09820986.9A patent/EP2346995B1/en active Active
- 2009-09-26 CN CN200980147515.1A patent/CN102227503B/zh not_active Expired - Fee Related
- 2009-09-26 EA EA201790824A patent/EA201790824A3/ru unknown
- 2009-09-26 KR KR1020117008744A patent/KR101724162B1/ko not_active Expired - Fee Related
- 2009-09-26 WO PCT/US2009/058510 patent/WO2010045002A2/en not_active Ceased
- 2009-09-26 EP EP09816967.5A patent/EP2344648B1/en active Active
- 2009-09-26 EP EP18198570.6A patent/EP3502256A3/en not_active Withdrawn
- 2009-09-26 MY MYPI2011001328A patent/MY156333A/en unknown
- 2009-09-26 JP JP2011529291A patent/JP5771147B2/ja not_active Expired - Fee Related
- 2009-09-26 CA CA2738472A patent/CA2738472A1/en not_active Abandoned
- 2009-09-26 MX MX2011003039A patent/MX2011003039A/es active IP Right Grant
- 2009-09-26 MX MX2015010159A patent/MX357418B/es unknown
- 2009-09-26 DK DK09820986.9T patent/DK2346995T3/en active
- 2009-09-26 EA EA201170492A patent/EA027693B1/ru not_active IP Right Cessation
- 2009-09-26 ES ES09820986T patent/ES2706899T3/es active Active
- 2009-09-26 AU AU2009303690A patent/AU2009303690B2/en not_active Ceased
- 2009-09-26 CN CN201510624987.9A patent/CN105624193B/zh not_active Expired - Fee Related
- 2009-09-26 JP JP2011529292A patent/JP5684130B2/ja not_active Expired - Fee Related
- 2009-09-26 BR BRPI0919113A patent/BRPI0919113A2/pt not_active IP Right Cessation
-
2011
- 2011-03-18 MX MX2018008440A patent/MX2018008440A/es unknown
- 2011-03-22 ZA ZA2011/02115A patent/ZA201102115B/en unknown
- 2011-03-22 IL IL211847A patent/IL211847A/en active IP Right Grant
- 2011-03-26 US US13/072,705 patent/US8722867B2/en active Active
- 2011-04-25 CO CO11050300A patent/CO6362050A2/es not_active Application Discontinuation
-
2014
- 2014-05-09 US US14/274,556 patent/US10035983B2/en active Active
-
2015
- 2015-01-14 JP JP2015004923A patent/JP5992548B2/ja not_active Expired - Fee Related
- 2015-05-13 JP JP2015097980A patent/JP6062485B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-17 JP JP2016159893A patent/JP6523224B2/ja not_active Expired - Fee Related
- 2016-11-08 IL IL248833A patent/IL248833B/en active IP Right Grant
-
2018
- 2018-07-24 US US16/044,472 patent/US20190185821A1/en not_active Abandoned
-
2019
- 2019-01-13 IL IL264214A patent/IL264214B/en not_active IP Right Cessation
- 2019-04-26 JP JP2019086133A patent/JP2019141088A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012503986A5 (enExample) | ||
| EP2909324B1 (en) | Retroviral vector with mini-promoter cassette | |
| EP1222300B1 (en) | Lentiviral vectors for the preparation of immunotherapeutical compositions | |
| Beyer et al. | Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range | |
| JP7672114B2 (ja) | 安定したレンチウイルスパッケージング細胞株およびその作成方法 | |
| EP2583974B1 (en) | Pseudotyping of foamy viruses | |
| JP2016526920A5 (enExample) | ||
| JP2016533769A (ja) | 抗体発現用バイシストロニック発現ベクター及びそれを用いた抗体の生産方法 | |
| US20070048285A1 (en) | Self-inactivating retroviral vector | |
| JP2015533510A5 (enExample) | ||
| JP7759318B2 (ja) | 産生系 | |
| WO2014016383A9 (en) | Glycoproteins for pseudotyping lentivectors | |
| US20060084093A1 (en) | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins | |
| JP2014525754A (ja) | アポトーシスを誘導するための組成物および方法 | |
| Froelich et al. | Lentiviral vectors for immune cells targeting | |
| US20120009162A1 (en) | T cell receptor and nucleic acid encoding the receptor | |
| US20240401077A1 (en) | Koala retrovirus envelope gylcoproteins and uses thereof | |
| WO2018119519A1 (en) | Ghr-106 chimeric antigen receptor construct and methods of making and using same | |
| Ebrahimabadi et al. | Design and construction of a recombinant lentiviral vector with specific tropism to human epidermal growth factor‐overexpressed cancer cells: Developing a new retargeting system for lentivirus vectors | |
| Cannon et al. | Retroviral vectors for gene therapy | |
| WO2015053398A1 (ja) | 高力価レトロウイルスベクター | |
| US20020164583A1 (en) | Targeting viral vectors to specific cells | |
| Grabarczyk et al. | Expression of PiT1 and PiT2 retroviral receptors and transduction efficiency of tumor cells. | |
| EP1511767B1 (en) | A purified polypeptide, isolated nucleic acids encoding said polypeptide, vectors and use thereof | |
| CA3048312A1 (en) | Rp215 chimeric antigen receptor construct and methods of making and using same |